Spectrum Pharmaceuticals Added to the Russell Global(R), Russell 3000(R) and Russell 2000(R) Indexes

Spectrum Pharmaceuticals Added to the Russell Global(R), Russell 3000(R) and Russell 2000(R) Indexes
http://www.spectrumpharm.com/presentations/corporate/index.html

IRVINE, Calif., Jun 29, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced that Russell Investments has added Spectrum Pharmaceuticals to the Russell Global(R), the Russell 3000(R) and the Russell 2000(R) Indexes. Russell Investments produces a family of market cap-weighted U.S. equity indexes. All U.S. indexes are subsets of the Russell 3000E(TM) Index, which represents approximately 99% of the U.S. equity market.

"We are pleased to be a component of the Russell indexes," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Since our inception, we have been focused on building sustainable shareholder value for our shareholders. We believe that our addition to the Russell indexes is a direct result of this focus."
Over the past 25 years, Russell's innovative methodology has helped their indexes become the benchmarks most used by institutional investors. Currently, institutional investment professionals responsible for over $4.3 trillion in assets use Russell indexes to guide their portfolios.

In order to maintain indexes that are truly representative of global equity markets, Russell annually rebalances the entire Russell family of indexes. On the last trading day in May, Russell ranks the 4,000 largest U.S. stocks by market capitalization. After the initial list of 4,000 eligible participants is determined, the shares outstanding for each company are adjusted for corporate cross-ownership and large private holdings. Therefore, the Russell Indexes include only the investable portion of the universe--that segment in which investors can freely transact shares.
Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.

About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy. For more information, please visit the Company's website at http://www.spectrumpharm.com/.

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, building sustainable shareholder value for our shareholders and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.(R) is a registered trademark of Spectrum, TURNING INSIGHTS INTO HOPE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
Information regarding Russell Investments has been obtained from Russell Investments and not independently verified by Spectrum.
(C) 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
SOURCE: Spectrum Pharmaceuticals Spectrum Pharmaceuticals
Russell Skibsted, 949-788-6700 ext. 234
Sr. Vice President & Chief Business Officer
Paul Arndt, 949-788-6700 ext. 216
Senior Manager, Investor Relations
Business Wire 2009